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Abstract: Regioselective synthesis of novel ring A-fused arylpyrazoles of dihydrotestosterone (DHT)
was carried out in two steps under facile reaction conditions. Aldol condensation of DHT with
acetaldehyde afforded a 2-ethylidene derivative regio- and stereo-selectively, which was reacted
with different arylhydrazines in the presence of iodine via microwave-assisted oxidative cyclization
reactions. The 17-keto analogs of steroidal pyrazoles were also synthesized by simple oxidation in order
to enlarge the compound library available for pharmacological studies and to obtain structure–activity
relationship. The antiproliferative activities of the structurally related heteroaromatic compounds
were tested in vitro on human cervical and breast adenocarcinoma cell lines (HeLa, MCF-7 and
MDA-MB-231) and on two androgen-independent malignant prostate carcinoma cell lines (PC-3 and
DU 145). Based on primary cytotoxicity screens and IC50 assessment, a structure-function relationship
was identified, as derivatives carrying a hydroxyl group on C-17 exhibit stronger activity compared
to the 17-one counterparts. Cancer cell selectivity of the derivatives was also determined using
non-cancerous MRC-5 cells. Furthermore, the proapoptotic effects of some selected derivatives were
verified on androgen therapy refractive p53-deficient PC-3 cells. The present study concludes that
novel DHT-derived arylpyrazoles exert cancer cell specific antiproliferative activity and activate
apoptosis in PC-3 cells.
Keywords: dihydrotestosterone; heterocyclization; pyrazoles; regioselectivity; prostate cancer;
anti-cancer effect; apoptosis
1. Introduction
Endogenous androgenic-anabolic steroids (AAS), such as testosterone (T) and its more active
derivative, dihydrotestosterone (DHT) play a key role in the development and progression of
hormone-dependent prostate cancer in men [1] and may also exert a direct activating or inhibitory
effect on the growth of certain female breast cancers primarily by influencing the androgen receptor
(AR) signaling pathway [2,3].
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Since AR signaling is a substantial factor in malignant cell proliferation within the prostate
tissue [4,5], the first-line therapy often involves hormone deprivation either via surgical manipulation
of the endocrine system or by the exogenous administration of drugs. These procedures will ultimately
reduce the levels of sex hormones by inhibiting their production, or block the action of the endogenous
ligand by binding to the hormone receptor, thereby preventing its activation [6]. Unfortunately, prostate
cancer cells are able to develop different resistance mechanisms over time to maintain AR signaling
and to circumvent the reduced synthesis and the blocked action of androgens [7]. As a consequence, a
castration resistant stage of the disease evolves, for which there is no life-prolonging therapy to date.
AR-signaling plays a crucial role in AR+ breast cancers as well, however, in such cases coordination of
the cellular features and actions is quite complex and depends on the presence or absence of other
signaling mechanisms [8]. For instance, early studies have demonstrated proliferation promoting as
well as antiproliferative effects of androgens on cell activity, depending largely on the specific breast
cancer subtype [9].
All of the therapies employ drugs—alone or in combination—mostly for aiming at the
hormone-signaling pathway. However occasionally, hormone receptor-independent mechanisms
are targeted as well, those in particular, which were compromised during cancer development
and progression to modulate cell cycle regulation and support cellular proliferative properties.
For example, experimental results revealed that some heterocyclic steroidal derivatives can influence
microtubule dynamics [10] and apoptosis [11] in a hormone receptor-independent manner by inhibiting
tubulin polymerization and upregulating key factors involved in triggering the intrinsic apoptotic
pathway [12–14]. The main advantage of aiming these cellular features is to offer a solution for the
therapy of hormone-resistant cancers. Yet when steroidal compounds of such mode of action are
applied, the primary hormonal effect is undesirable, therefore, structural modifications are needed in
order to reduce or eliminate the ability of the molecule to interact with the androgen and estrogen
receptors. Based on extensive structure–activity relationship studies and our knowledge about the
exact structure and ligand binding site of hormone receptor proteins [15,16], new derivatives lacking
the structural features necessary for receptor binding can be properly designed.
Amongst semi-synthetic androgens, relatively few DHT derivatives with a ring A-fused heterocycle
have been synthesized so far (Figure 1). The presence of the 17β-OH group of DHT is essential, while
the 3-keto group is favorable for binding to the AR [17]. Thus, the hormonal effect can be reduced
or eliminated by a significant structural change at these or nearby positions. Moreover, according to
structure–activity relationship studies, steric rather than electronic factors are decisive for the structural
requirements at C-2 and/or C-3 in androgens [18]. It is also important to emphasize that DHT and
its derivatives are not aromatizable androgens [19], hence, they are not able to exert estrogen-like
effects in the body by binding to estrogen receptors. Earlier, structural modifications of DHT were
directed to achieve a separation of androgenic and anabolic effects, and therefore some derivatives,
such as prostanozol, stanozolol, androisoxazole, furazabol and danazol bearing a 2,3-fused heteroring
have been synthesized (Figure 1). These compounds exhibit a better anabolic-to-androgenic ratio
than the natural compound, i.e., the androgenic activity is reduced, while the anabolic action is
retained or enhanced by the incorporation of the heterocyclic moiety. Nevertheless, it has to be noted
that several of these derivatives possess unpredictable endocrinological activities [15]. Interestingly,
antiandrogenic effect without any other hormonal activities prevails for zanoterone, a compound with
a substitution at the pyrazole-N [20]. In spite of the obvious fact that the incorporation of different
heterorings to 2,3 position of DHT and to its analogs may significantly alter the bioactivity of the
parent molecule, very few examples are to be found in the literature for such kind of transformations.
In this respect, we previously demonstrated that different heteroaryl-fused derivatives of DHT exert
significant antiproliferative effect in vitro on human cancer cell lines of diverse origins [21–23].
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Figure 1. Ring-A condensed heterocyclic derivatives of dihydrotestosterone (DHT) with marked 
biological activities. 
In view of the potential biological significance of heterocyclic DHT analogs, and the well-known 
antiproliferative potential of numerous steroids containing pyrazoline or pyrazole scaffolds [24–27], 
we now describe a facile, one-pot heterocyclization/oxidation sequence of a DHT-derived steroidal 
enone with different arylhydrazines in the presence of iodine under microwave (MW) conditions. 
The stepwise sequence, i.e., the cyclocondensation of the unsaturated ketone to pyrazolines, and the 
subsequent oxidation to pyrazoles was also investigated. Finally, the 17-keto derivatives were 
synthesized as well in order to enlarge the compound library available for pharmacological studies. 
All of the synthesized compounds were primarily screened in vitro for their antiproliferative activity 
on five different cancer cell lines, namely DU 145, PC-3, HeLa, MCF-7 and MDA-MB-231 and on non-
cancerous MRC-5 fibroblasts. Our results indicate that several compounds exhibit cancer cell specific 
and dose dependent inhibition of cell growth. Based on these data, five compounds featuring 
outstanding cancer cell specificity were selected for further experiments i.e., to determine IC50 values. 
Annexin V–propidium iodide staining and quantitative-real time PCR were performed to examine 
in details the proapoptotic activity of selected ring A-fused arylpyrazole derivatives of DHT on 
androgen therapy refractive p53 deficient PC-3 cells. 
2. Results and Discussion 
2.1. Synthetic Studies 
For the synthesis of steroidal ring A-fused pyrazole derivatives, DHT was first subjected to aldol 
condensation with an excess of acetaldehyde in alkaline ethanol at low temperature in order to obtain 
the starting α,β-enone suitable for heterocyclization. Although the similar aldol-type Claisen–
Schmidt reaction of cyclic ketones with different arylaldehydes is frequently applied for the efficient 
synthesis of arylidene ketones [28,29], the use of acetaldehyde is fairly unusual due to its greater 
reactivity and ability to undergo undesirable self-condensation [30]. Nevertheless, the transformation 
led to the regioselective formation of 2-ethylidene-DHT (1) in good yield (70%) after purification by 
column chromatography (Table 1). The expected (E)-configuration along the double bond was 
evidenced by NOESY correlations between the 1β-H and 21-CH3 protons (Supplementary Material). 
Preliminary ring-closure experiments on 1 with phenylhydrazine hydrochloride 2a in the 
presence of p-toluenesulfonic acid (PTSA) were first carried out both under conventional heating 
Figure 1. Ring-A condensed heterocyclic derivatives of dihydrotestosterone (DHT) with marked
biological activities.
In view of the potential biological significance of heterocyclic DHT analogs, and the well-known
antiproliferative potential of numerous steroids containing pyrazoline or pyrazole scaffolds [24–27],
we now describe a facile, one-pot heterocyclization/oxidation sequence of a DHT-derived steroidal
enone with different arylhydrazines in the presence of iodine under microwave (MW) conditions.
The stepwise sequence, i.e., the cyclocondensation of the unsaturated ketone to pyrazolines, and
the subsequent oxidation to pyrazoles was also investigated. Finally, the 17-keto derivatives were
synthesized as well in order to enlarge the compound library available for pharmacological studies.
All of the synthesized compounds were primarily screened in vitro for their antiproliferative activity
on five different cancer cell lines, namely DU 145, PC-3, HeLa, MCF-7 and MDA-MB-231 and on
non-cancerous MRC-5 fibroblasts. Our results indicate that several compounds exhibit cancer cell
specific and dose dependent inhibition of cell growth. Based on these data, five compounds featuring
outstanding cancer cell specificity were selected for further experiments i.e., to determine IC50 values.
Annexin V–propidium iodide staining and quantitative-real time PCR were performed to examine in
details the proapoptotic activity of selected ring A-fused arylpyrazole derivatives of DHT on androgen
therapy refractive p53 deficient PC-3 cells.
2. Results and Discussion
2.1. Synthetic Studies
For the synthesis of steroidal ring A-fused pyrazole derivatives, DHT was first subjected to aldol
condensation with an excess of acetaldehyde in alkaline ethanol at low temperature in order to obtain
the starting α,β-enone suitable for heterocyclization. Although the similar aldol-type Claisen–Schmidt
reaction of cyclic ketones with different arylaldehydes is frequently applied for the efficient synthesis
of arylidene ketones [28,29], the use of acetaldehyde is fairly unusual due to its greater reactivity and
ability to undergo undesirable self-condensation [30]. Nevertheless, the transformation led to the
regioselective formation of 2-ethylidene-DHT (1) in good yield (70%) after purification by column
chromatography (Table 1). The expected (E)-configuration along the double bond was evidenced by
NOESY correlations between the 1β-H and 21-CH3 protons (Supplementary Material).
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Preliminary ring-closure experiments on 1 with phenylhydrazine hydrochloride 2a in the presence
of p-toluenesulfonic acid (PTSA) were first carried out both under conventional heating (Method A)
and MW conditions (Method B), and a mixture of pyrazoline diastereomers of 3a was obtained owing
to the formation of two new chiral centers on C-2 and C-5′ (Scheme 1). The MW-assisted method
greatly shortened the reaction time, but the yields of the desired products were only slightly better
than in the thermally-induced version. The stereoisomers of 3a could not be separated by column
chromatography and spontaneous oxidation of the pyrazoline moiety to the corresponding pyrazole
during purification was also observed. In view of the tendency of pyrazolines to undergo autoxidation,
further experiments toward their stereoselective synthesis were not performed. Mild oxidation of the
diastereomeric mixture of 3a to a single heteroaromatic pyrazole (4a) was successfully achieved with
diacetoxyiodobenzene (DIB) in dichloromethane (DCM) at room temperature, but the product was
obtained only with a moderate yield (64%) after purification (Scheme 1). At the same time, complete
oxidation of 3a with the Jones reagent in acetone affected both the pyrazoline ring and the 17-OH
group, which resulted in the corresponding heteroaromatic 17-keto derivative 5a with a yield of 41%.
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equiv.), EtOH, MW, 100 °C, 2 min; Method C: I2 (0.5 equiv.), EtOH, MW, 100 °C, 2 min. 
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Entry R1 R2 Arylhydrazine Compound Yield (%) 1 Compound Yield (%) 1 
1 H H 2a 4a 85 5a 96 
2 CH3 H 2b 4b 88 5b 93 
3 H CH3 2c 4c 82 5c 92 
4 CH3 CH3 2d 4d 80 5d 94 
5 H OMe 2e 4e 89 5e 92 
6 H F 2f 4f 82 5f 95 
7 H Cl 2g 4g 83 5g 93 
8 H Br 2h 4h 80 5h 92 
9 H CN 2i 4i 81 5i 92 
10 H NO2 2j 4j 85 5j 96 
1 After purification by flash chromatography. 
In order to avoid the multistep synthesis and to improve the yield of the desired pyrazole 4a, a 
one-pot procedure, involving the I2-mediated oxidative cyclization [31] of 1 with different 
Scheme 1. Synthesis of ring A-fused arylpyrazole derivatives of DHT. Reagents and conditions: Method
A: p-toluenesulfonic acid (PTSA) (0.5 equiv.), EtOH, reflux, 78 ◦C, 1 h; Method B: PTSA (0.5 equiv.),
EtOH, MW, 100 ◦C, 2 min; Method C: I2 (0.5 equiv.), EtOH, MW, 100 ◦C, 2 min.
Table 1. Yields of ring A-fused arylpyrazole derivatives of DHT obtained by Method C (4a–j) and
subsequent oxidation (5a–j).
Entry R1 R2 Arylhydrazine Compound Yield (%) 1 Compound Yield (%) 1
1 H H 2a 4a 85 5a 96
2 CH3 2b 4b 88 5b 93
3 H CH3 2c 4c 82 5c 92
4 CH3 CH3 2d 4d 80 5d 94
5 H OMe 2e 4e 89 5e 92
6 H F 2f 4f 82 5f 95
7 H Cl 2g 4g 83 5g 93
8 H Br 2h 4h 80 5h 92
9 H CN 2i 4i 81 5i 92
10 H NO2 2j 4j 85 5j 96
1 After purification by flash chromatography.
In order to avoid the multistep synthesis and to improve the yield of the desired pyrazole
4a, a one-pot procedure, involving the I2-mediated oxidative cyclization [31] of 1 with different
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arylhydrazines (2a–j) has been developed under MW condition (Scheme 1, Method C). The improved
practical protocol led to ring A-fused arylpyrazoles (4a–j) in excellent yields (81–89%) without the
necessity of isolating the less stable pyrazoline intermediates (Table 1, entries 1–10). Subsequent
oxidation of the 17β-hydroxy derivatives (4a–j) with the Jones reagent also made the 17-keto analogs
(5a–j) readily available for pharmacological comparison.
The structure of the synthesized compounds was confirmed by 1H and 13C NMR measurements,
which indicated the presence of the characteristic signals of the aromatic ring from the arylhydrazine
reagent and the tri-substituted pyrazole moiety formed by the ring-closure reaction (Supplementary
Material). The acid-catalyzed heterocyclization of arylhydrazines with α,β-enones can occur either by
1,2- [32] or 1,4-addition [33] leading to two different regio-isomeric pyrazoles. Therefore, 2D NMR
spectra were recorded for a representative compound (4a) in order to determine the exact structure.
After identification of the related 1H and 13C signals with the help of HSQC (Heteronuclear Single
Quantum Correlation) and HMBC (Heteronuclear Multiple Bond Correlation) spectra, the orientation
of the pyrazole ring was determined on the basis of through-space (NOESY) correlations. Thus, spatial
proximity was evidenced by cross-peaks between 2”-H–5′-CH3, 5′-CH3–1β-H, 1β-H–19-CH3 and
4β-H–19-CH3 supporting the exclusive formation of regio-isomer 4a (Figure 2). Taking into account
that the terminal nitrogen in arylhydrazines is more nucleophilic than the internal one [23], the reaction
of 1 with 2a–j is considered to proceed via hydrazone intermediates followed by intramolecular
ring-closure. The NMR spectra recorded for the oxidized products (5a–j) also confirmed the expected
structures (Supplementary Material). The only difference compared to the 1H spectra of compounds
4a–j is the disappearance of the triplet signal of 17α-H at 3.65 ppm. At the same time, the signal of
carbonyl-C could be observed at around 221 ppm in the 13C NMR spectra instead of the C-17 signal at
81.9 ppm characteristic for 4a–j.
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2.2. Pharmacological Studies
2.2.1. Cell Type Specific Antiproliferative Action of DHT-Derived Arylpyrazoles
To perform pharmacological studies, the synthesized DHT derivatives were dissolved in DMSO
(dimethyl sulfoxide) in a final concentration of 5 mM. One compound (5h) was non-soluble in the
applied solvent, thus was excluded from the pharmacological evaluations. Cancer cell specific growth
inhibition exhibited by the ring-condensed pyrazole derivatives applied in 10 µM and in 30 µM
concentrations was screened and the effect of each compound on cell viability was assessed. For this,
PC-3 and DU 145 prostate cancer cells, MCF-7 and MDA-MB-231 breast cancer cells, HeLa cervical
cancer cells and non-cancerous MRC-5 fibroblasts were used. Based on viability data a heat map
(Figure 3) was constructed showing differential activities exhibited by the analogs depending on the
tested cell type (represented as viability in %). All compounds showed concentration-dependent
antiproliferative action as 30 µM concentrations were generally more effective than 10 µM. On the heat
map representing viability results following treatments with DHT derivatives at 30 µM concentration
a remarkable structure–function relationship can be recognized (Figure 3). Most of the derivatives of
the series 4, which carry a hydroxyl group on C-17 (4a–j) exhibited more potent cancer cell growth
inhibition compared to the 17-one counterparts (5a–j), thus, the presence of the OH-group at C-17
seems to have a determining role in the biological activity of these pharmacological candidates. Among
all examined compounds, 4e showed the utmost specificity in cancer cell toxicity, which manifested
already at 10 µM concentration. In addition to 4e, the primary screen also resulted in several positive
hits regarding prostate cancer or in most cases rather PC-3 cell specificity. Among them especially
4a, 4b, 4c, 4g, 4i, 4j, 5f, 5g and 5j featured significantly higher antiproliferative potency against PC-3
prostate cancer cells compared to MRC-5 non-cancerous fibroblasts at 10 µM and 4i, 4j, 5b, 5e, 5f and
5j at 30 µM concentration.
Therefore, as a hit validation, the IC50 values of five selected compounds (4a, 4e, 4g, 4j and 5j)
were determined on all the applied cancer cell lines and on non-cancerous fibroblasts (Figure S1a and
S1b). The IC50 values of the five compounds were generally markedly lower on cancer cell lines than
on non-cancerous MRC-5 cells (Table 2). The selective toxic effects of these compounds were especially
prominent on PC-3 cells, marked by the lowest IC50 values.
Comparing the performance of these compounds with clinically applied chemotherapeutic drugs
like cisplatin—based on the IC50 values of cisplatin (230.9 ± 1.37 µM on PC-3, 126.8 ± 1.18 µM on DU
145 and 237.3 ± 1.16 µM on MRC-5 cells) assessed previously [21]—we observe that the tested DHT
derivatives all performed better than cisplatin on the examined prostate cancer cell lines (Table 2).
These findings are highly relevant, especially related to PC-3 cells, since these cells are considered to
have a high metastatic potential, lack functional p53 and are relatively unresponsive to androgens.
Therefore, our further experiments were conducted only on PC-3 prostate cancer cells with two selected
compounds 4e and 4j.
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Figure 3. Primary antiproliferative action of the synthesized DHT derivatives on different cell lines.
Table 2. IC50 values (µM ± SD) of the selected compounds determined on various cancer cell lines and
on non-cancerous MRC-5 cells.
4a 4e 4g 4j 5j
MRC-5 23.7 ± 2.3 8.6 ± 1.3 15.6 ± 1.4 >30 25.5 ± 2.3
DU 145 9.2 ± 1.2 3.6 ± 1.2 14.2 ± 1.3 19.7 ± 1 13.5 ± 1.1
PC-3 5.6 ±1.2 4.2 ± 1.1 7.7 ± 1.2 5.6 ± 1.1 6.7 ± 1.1
HeLa 16.9 ± 3.7 8.5 ± 0.6 7.2 ± 0.4 >30 10.4 ± 0.1
MCF-7 12.9 ± 0.1 5.5 ± 0.6 4.4 ± 0.3 18.2 ± 3.9 11.3 ± 2.8
MDA-MB-231 15.3 ± 3.4 6.6 ± 0.9 12.6 ± 1.5 >30 >30
2.2.2. Apoptosis-Inducing Properties of Selected DHT Derivatives on PC-3 Prostate Cancer Cells
The counter-balance of cell proliferation and death is necessary to maintain normal cell
turnover, hence they are programmed and regulated precisely. Upregulation of proliferation and/or
downregulation of cell death mechanisms are generally associated with cancer development [34].
Among various programmed cell death mechanisms, deregulation of apoptosis drives the growth of a
large number of cancers including prostate cancer. It has already been shown that PC-3 cells have
unique cellular features to cope with various stress situations partly due to the inability to express
the tumor suppressor p53. This protein normally serves as a multifunctional platform to overcome
cellular impairments such as DNA damage, oxidative stress, activation of oncogenes, hypoxia and heat
shock [35]. Activation of p53 leads to enhanced transcription of p53 responsive genes, which mediate
cell cycle arrest and initiate apoptosis [36].
A structurally related and similarly effective cell growth inhibiting androstane derivative elicited
apoptosis as evidenced by increased hypodiploid (subG1) cell population on MDA-MB-231 breast
cancer cells [23]. Therefore, we aimed to find out whether DHT-derived pyrazoles are capable of
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inducing apoptosis and/or necrosis in p53 deficient PC-3 cells and whether these mechanisms lay
behind the observed anti-cancer effects of the selected derivatives. Along this line, PC-3 prostate
cancer cells were treated with either 4e, 4j or for comparison, with cisplatin. We performed annexin
V/PI apoptosis detection assay and the results (Figure 4a) indicate that 4e and 4j treatments induced
significant apoptosis marked by the high percentage of annexin V-positive cells (Q2 + Q3) 33.96% and
37.89%, respectively, whereas less than 1% annexin V-positive cells were detected in the untreated
control (Figure 4b). Cisplatin treatment also led to a prominent apoptosis in our experimental set-up.
The percentage of only PI-positive cells (Q1) was not changed following treatments, therefore DHT
derivatives do not seem to induce necrosis directly. To further verify apoptosis activation in PC-3 cells,
we performed quantitative real-time PCR and examined the transcriptional activation of apoptotic
markers caspase 3 and Bax. Our results (Figure 4c) show significantly increased caspase 3 and Bax
mRNA expression levels, supporting the activation of apoptotic cell death pathway in 4e and 4j as
well as in cisplatin treated PC-3 cells compared to untreated control. These results suggest that both
derivatives (4e and 4j) induce apoptosis in PC-3 prostate cancer cells.Int. J. Mol. Sci. 2019, 20, x 9 of 20 
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could be exploited in chemotherapy drug design and development. Since we observed prominent
antiproliferative actions and massive induction of apoptotic cell death following 4e and 4j treatments,
we believe that PC-3 cells can be effectively eliminated by selected DHT derivatives. The fact that
p53-independent apoptosis can be triggered by these compounds, enhances their potential as cancer
therapy candidates.
3. Materials and Methods
3.1. Chemistry
3.1.1. General Information
Reagents and materials were purchased from commercial suppliers (TCI, Tokyo, Japan; Alfa Aesar,
Haverhill, MA, USA and Sigma-Aldrich Corporation, St. Louis, MO, USA). All solvents were dried
and purified according to standard procedures. MW-assisted reactions were carried out with a CEM
Discover SP instrument (CEM Corporation, Matthews, NC, USA) using a maximum power of 200 W
with dynamic control program. Thin layer chromatography (TLC) was carried out on Kieselgel-G
(Si 254 F, Merck KGaA, Darmstadt, Germany) plates (0.25 mm thick). The spots were detected by
spraying with phosphomolybdic acid (5%) in aqueous phosphoric acid (50%) or visualized with UV
light 254 nm. The products were purified with preparative column chromatography on Merck silica
gel 60, 40–63 µm (Merck KGaA). Melting points (Mps) were measured on an SRS Optimelt digital
device (Stanford Research Systems Inc, Sunnyvale, CA, USA). Elementary analysis data were obtained
with a PerkinElmer CHN analyzer model 2400 (PerkinElmer Inc, Waltham, MA, USA). NMR spectra
were recorded at 298 K with a Bruker DRX 500 instrument (Bruker, Billerica, MA, USA). Chemical
shifts are reported in ppm (δ scale) and coupling constants (J) in Hz. The 1H resonance signals are
indicated as a singlet (s), a doublet (d), a double doublet (dd), a triplet (t), a triplet of doublets (td)
or a multiplet (m). 13C NMR spectra are 1H-decoupled. The J-MOD pulse sequence was applied
to determine multiplicities. An HPLC/MSD system was used for automated flow injection analyses.
Components of the system: An Agilent 1100 micro vacuum degasser (Agilent Technologies, Santa
Clara, CA, USA) a quaternary pump, a micro-well plate autoinjector and a 1946A MSD equipped
with an electrospray ion source (ESI) operated in positive ion mode. ESI parameters: Nebulizing gas
N2, at 35 psi; drying gas N2, at 350 ◦C and 12 L/min; capillary voltage 3000 V; fragmentor voltage
70 V. The MSD was operated in scan mode with a mass range of m/z 60−620. Samples (0.2 µL) were
injected directly into the solvent flow (0.3 mLl/min) of CH3CN/H2O 70:30 (v/v) supplemented with 0.1%
formic acid with automated needle wash. Agilent LC/MSD Chemstation software (C.01.08, Agilent
Technologies Inc) was used to control the system.
3.1.2. Synthesis of 2-Ethylidene-DHT (1)
DHT (2.9 g, 10 mmol) and KOH (561 mg, 10 mmol) were dissolved in absolute EtOH (40 mLl),
and the homogenous solution was cooled to approximately −10 ◦C in an ice bath containing sodium
chloride. (Cooling was applied during the whole procedure.) Afterward, acetaldehyde (1.01 mLl,
18 mmol) was added to the mixture and it was stirred at the given temperature. After 1.5 h, a further
amount of acetaldehyde (0.25 mLl, 4.5 mmol) was added to the reaction mixture and it was stirred for
2 h. After completion of the reaction, the pH was adjusted to around 7 with 1 M H2SO4 solution in
EtOH, and the mixture was evaporated in vacuo. The residual oil was dissolved in EtOAc and washed
with water (2 x 10 mLl), then the combined organic layers were dried over anhydrous Na2SO4 and
evaporated in vacuo. The crude product was purified by column chromatography with EtOAc/CH2Cl2
= 2:98. Yield: 2.2 g (white solid); Mp 137–141 ◦C; Anal. Calcd. for C21H32O2 (316.49): C, 79.70; H,
10.19. Found: C, 79.84; H, 10.25. 1H NMR (CDCl3, 500 MHz): δ 0.76 (s, 3H, 18-H3), 0.81 (s, 3H, 19-H3),
0.83–1.01 (overlapping m, 3H), 1.11 (m, 1H), 1.18–1.31 (overlapping m, 2H), 1.35–1.47 (overlapping m,
4H), 1.58–1.70 (overlapping m, 5H), 1.72 (dd, 3H, J = 7.2 Hz, J = 2.2 Hz, 21-H3), 1.84 (d, 1H, J = 15.2 Hz,
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1α-H), 1.87 (m, 1H), 2.06 (m, 1H, 16α-H), 2.14 (dd, 1H, J = 18.5 Hz, J = 13.2 Hz, 4β-H), 2.33 (dd, 1H,
J = 18.5 Hz, J = 5.2 Hz, 4α-H), 2.76 (d, 1H, J = 15.2 Hz, 1β-H), 3.65 (t, 1H, J = 8.6 Hz, 17α-H), 6.74 (m,
1H, 20-H); 13C NMR (CDCl3, 125 MHz): δ 11.0 (C-18), 11.8 (C-19), 13.6 (C-21), 20.9 (C-11), 23.4 (C-15),
28.4 (C-6), 30.5 (C-16), 31.0 (C-7), 35.4 (C-8), 35.6 (C-10), 36.6 (C-12), 39.7 (C-1), 42.5 (C-5), 42.7 (C-4), 42.8
(C-13), 50.9 (C-14), 53.7 (C-9), 81.8 (C-17), 135.7 (C-20), 136.1 (C-2), 200.8 (C-3); ESI-MS 317 [M+H]+.
3.1.3. General Procedure for the One-Pot Synthesis of Ring A-Condensed Pyrazoles 4a–j under MW
Irradiation (Method C)
To a solution of 1 (187 mg, 0.60 mmol) in absolute EtOH (5 mLl), I2 (152 mg, 0.6 mmol) and
(substituted) phenylhydrazine hydrochloride (2a–j, 1.20 mmol) were added and the mixture was
irradiated in a closed vessel at 100 ◦C for 2 min. After completion of the reaction, the mixture was
poured into saturated aqueous solution of Na2S2O3 (10 mLl) and extracted with CH2Cl2 (3× 10 mLl).
The combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo. The crude
product was purified by column chromatography with EtOAc/CH2Cl2 = 5:95.
17β-Hydroxy-1′-phenyl-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4a)
According to the general procedure, phenylhydrazine hydrochloride (2a, 174 mg) was used. Yield:
206 mg (85%, white solid); Mp 241–245 ◦C; Anal. Calcd. for C27H36N2O (404.60): C, 80.15; H, 8.97.
Found: C, 80.02; H, 8.90. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.81 (s, 3H, 19-H3), 0.84–1.02
(overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.7, J = 3.7 Hz, 12α-H), 1.27 (m, 1H,
15β-H), 1.33–1.51 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.53–1.66 (overlapping m, 3H,
5α-H, 15α-H and 6α-H), 1.67–1.75 (overlapping m, 2H, 11α-H and 7β-H), 1.86 (m, 1H, 12β-H), 2.05
(d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.21 (s, 3H, 5′-CH3), 2.34 (dd, 1H, J = 16.8 Hz, J = 11.9 Hz,
4β-H), 2.52 (d, 1H, J = 15.0 Hz, 1β-H), 2.67 (dd, 1H, J = 16.8 Hz, J = 5.1 Hz, 4α-H), 3.65 (t, 1H, J = 8.6 Hz,
17α-H), 7.32 (m, 1H, 4”-H), 7.43 (d, 4H, J = 4.4 Hz, 2”-H, 3”-H, 5”-H and 6”-H); 13C NMR (CDCl3, 125
MHz): δ 10.9 (5′-CH3), 11.0 (C-18), 11.8 (C-19), 20.8 (C-11), 23.4 (C-15), 27.4 (C-4), 29.2 (C-6), 30.5 (C-16),
31.3 (C-7), 34.8 (C-1), 35.8 (C-8), 36.2 (C-10), 36.7 (C-12), 42.4 (C-5), 42.8 (C-13), 50.9 (C-14), 54.0 (C-9),
81.9 (C-17), 115.1 (C-2), 124.5 (2C, C-2” and C-6”), 127.1 (C-4”), 129.0 (2C, C-3” and C-5”), 135.4 (C-5′),
139.6 (C-1”), 148.4 (C-3); ESI-MS 405 [M+H]+.
17β-Hydroxy-1′-(2”-tolyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4b)
According to the general procedure, 2-tolylhydrazine hydrochloride (2b, 190 mg) was used. Yield:
221 mg (88%, white solid); Mp 225–227 ◦C; Anal. Calcd. for C28H38N2O (418.63): C, 80.34; H, 9.15.
Found: C, 80.27; H, 9.22. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.81 (s, 3H, 19-H3), 0.85–1.01
(overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 13.0, J = 3.7 Hz, 12α-H), 1.27 (m, 1H,
15β-H), 1.35–1.51 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.56–1.65 (overlapping m, 3H,
5α-H, 15α-H and 6α-H), 1.67–1.76 (overlapping m, 2H, 11α-H and 7β-H), 1.86 (m, 1H, 12β-H), 1.95 (s,
3H), 2.04 (s, 3H), 2.08 (d + m, 2H, J = 15.2 Hz, 1α-H and 16α-H), 2.21 (s, 3H, 5′-CH3), 2.34 (dd, 1H,
J = 16.2 Hz, J = 12.4 Hz, 4β-H), 2.52 (d, 1H, J = 15.2 Hz, 1β-H), 2.67 (dd, 1H, J = 16.2 Hz, J = 4.5 Hz,
4α-H), 3.65 (t, 1H, J = 7.8 Hz, 17α-H), 7.19–7.33 (overlapping m, 4H, 3”-H, 4”-H, 5”-H and 6”-H); 13C
NMR (CDCl3, 125 MHz): δ 9.7 (5′-CH3), 11.1 (C-18), 11.8 (C-19), 17.3 (2”-CH3), 20.8 (C-11), 23.4 (C-15),
27.5 (C-4), 29.3 (C-6), 30.6 (C-16), 31.4 (C-7), 34.8 (C-1), 35.8 (C-8), 36.3 (C-10), 36.7 (C-12), 42.5 (C-5),
42.8 (C-13), 51.0 (C-14), 54.2 (C-9), 81.9 (C-17), 113.1 (C-2), 126.3 (CH), 128.0 (CH), 128.8 (CH), 130.8
(CH), 136.1, 136.2 and 138.6 (C-5′, C-1” and C-2”), 147.8 (C-3); ESI-MS 419 [M+H]+.
17β-Hydroxy-1′-(4”-tolyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4c)
According to the general procedure, 4-tolylhydrazine hydrochloride (2c, 190 mg) was used. Yield:
206 mg (82%, white solid); Mp 247–248 ◦C; Anal. Calcd. for C28H38N2O (418.63): C, 80.34; H, 9.15.
Found: C, 80.45; H, 9.24. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.81 (s, 3H, 19-H3), 0.83–1.01
(overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.7, J = 3.5 Hz, 12α-H), 1.28 (m, 1H,
15β-H), 1.34–1.50 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.54–1.66 (overlapping m, 3H,
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5α-H, 15α-H and 6α-H), 1.67–1.76 (overlapping m, 2H, 11α-H and 7β-H), 1.86 (m, 1H, 12β-H), 2.06
(d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.18 (s, 3H, 5′-CH3), 2.34 (dd, 1H, J = 16.8 Hz, J = 12.3 Hz,
4β-H), 2.38 (4”-CH3), 2.51 (d, 1H, J = 15.0 Hz, 1β-H), 2.67 (dd, 1H, J = 16.8 Hz, J = 4.8 Hz, 4α-H), 3.65 (t,
1H, J = 8.4 Hz, 17α-H), 7.22 (d, 2H, J = 8.1 Hz, 3”-H and 5”-H), 7.30 (d, 2H, J = 8.1 Hz, 2”-H and 6”-H);
13C NMR (CDCl3, 125 MHz): δ 10.8 (5′-CH3), 11.0 (C-18), 11.8 (C-19), 20.8 (C-11), 21.0 (4”-CH3), 23.4
(C-15), 27.5 (C-4), 29.2 (C-6), 30.6 (C-16), 31.4 (C-7), 34.9 (C-1), 35.8 (C-8), 36.3 (C-10), 36.8 (C-12), 42.5
(C-5), 42.8 (C-13), 51.0 (C-14), 54.1 (C-9), 81.9 (C-17), 114.7 (C-2), 124.5 (2C, C-2” and C-6”), 129.5 (2C,
C-3” and C-5”), 136.9, 137.2 and 137.4 (C-5′, C-1” and C-4”), 148.2 (C-3); ESI-MS 419 [M+H]+.
17β-Hydroxy-1′-(2”,4”-dimethylphenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4d)
According to the general procedure, 2,4-dimethylphenylhydrazine hydrochloride (2d, 207 mg)
was used. Yield: 208 mg (80%, white solid); Mp 209–211 ◦C; Anal. Calcd. for C29H40N2O (432.65):
C, 80.51; H, 9.32. Found: C, 80.40; H, 9.21. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.81 (s,
3H, 19-H3), 0.84–1.02 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.7, J = 3.5 Hz,
12α-H), 1.28 (m, 1H, 15β-H), 1.34–1.51 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.55–1.65
(overlapping m, 3H, 5α-H, 15α-H and 6α-H), 1.66–1.75 (overlapping m, 2H, 11α-H and 7β-H), 1.85 (m,
1H, 12β-H), 1.93 (s, 3H), 1.98 (s, 3H), 2.07 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.32 (m, 1H, 4β-H),
2.35 (s, 3H, 4”-CH3), 2.50 (d, 1H, J = 15.0 Hz, 1β-H), 2.65 (dd, 1H, J = 16.6 Hz, J = 4.4 Hz, 4α-H), 3.64 (t,
1H, J = 8.4 Hz, 17α-H), 7.01–7.10 (overlapping m, 3H, 3”-H, 5”-H and 6”-H); 13C NMR (CDCl3, 125
MHz): δ 9.7 (5′-CH3), 11.1 (C-18), 11.7 (C-19), 17.2 (2”-CH3), 20.8 (C-11), 21.1 (4”-CH3), 23.4 (C-15),
27.5 (C-4), 29.3 (C-6), 30.6 (C-16), 31.4 (C-7), 34.8 (C-1), 35.8 (C-8), 36.3 (C-10), 36.8 (C-12), 42.5 (C-5),
42.8 (C-13), 51.0 (C-14), 54.2 (C-9), 81.9 (C-17), 113.0 (C-2), 126.9, 127.7 and 131.4 (C-3”, C-5” and C-6”),
135.8, 135.9, 136.2 and 138.6 (C-5′, C-1”, C-2” and C-4”), 147.7 (C-3); ESI-MS 433 [M+H]+.
17β-Hydroxy-1′-(4”-methoxyphenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4e)
According to the general procedure, 4-methoxyphenylhydrazine hydrochloride (2e, 210 mg) was
used. Yield: 232 mg (89%, white solid); Mp 257–259 ◦C; Anal. Calcd. for C28H38N2O2 (434.62): C,
77.38; H, 8.81. Found: C, 77.49; H, 8.89. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.80 (s,
3H, 19-H3), 0.84–1.02 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.7, J = 3.2 Hz,
12α-H), 1.28 (m, 1H, 15β-H), 1.33–1.50 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.52–1.65
(overlapping m, 3H, 5α-H, 15α-H and 6α-H), 1.67–1.75 (overlapping m, 2H, 11α-H and 7β-H), 1.86
(m, 1H, 12β-H), 2.06 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.15 (s, 3H, 5′-CH3), 2.34 (dd, 1H,
J = 16.5 Hz, J = 12.2 Hz, 4β-H), 2.50 (d, 1H, J = 15.0 Hz, 1β-H), 2.66 (dd, 1H, J = 16.5 Hz, J = 4.7 Hz,
4α-H), 3.65 (t, 1H, J = 8.4 Hz, 17α-H), 3.83 (4”-OMe), 6.94 (d, 2H, J = 8.4 Hz, 3”-H and 5”-H), 7.32 (d,
2H, J = 8.4 Hz, 2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.7 (5′-CH3), 11.0 (C-18), 11.8 (C-19),
20.8 (C-11), 23.4 (C-15), 27.5 (C-4), 29.2 (C-6), 30.6 (C-16), 31.4 (C-7), 34.9 (C-1), 35.8 (C-8), 36.3 (C-10),
36.8 (C-12), 42.5 (C-5), 42.8 (C-13), 51.0 (C-14), 54.1 (C-9), 55.5 (4”-OMe), 81.9 (C-17), 114.1 (2C, C-2”
and C-6”), 114.4 (C-2), 126.1 (2C, C-3” and C-5”), 133.1 (C-1”), 135.3 (C-5′), 148.0 (C-3), 158.6 (C-4”);
ESI-MS 435 [M+H]+.
17β-Hydroxy-1′-(4”-fluorophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4f)
According to the general procedure, 4-fluorophenylhydrazine hydrochloride (2f, 195 mg) was
used. Yield: 208 mg 82%, (white solid); Mp 244–246 ◦C; Anal. Calcd. for C27H35FN2O (422.59): C,
76.74; H, 8.35. Found: C, 76.85; H, 8.22. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.80 (s,
3H, 19-H3), 0.84–1.01 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.8, J = 4.2 Hz,
12α-H), 1.28 (m, 1H, 15β-H), 1.34–1.50 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.53–1.65
(overlapping m, 3H, 5α-H, 15α-H and 6α-H), 1.66–1.75 (overlapping m, 2H, 11α-H and 7β-H), 1.86
(m, 1H, 12β-H), 2.06 (d + m, 2H, J = 15.1 Hz, 1α-H and 16α-H), 2.17 (s, 3H, 5′-CH3), 2.33 (dd, 1H,
J = 16.8 Hz, J = 12.1 Hz, 4β-H), 2.51 (d, 1H, J = 15.1 Hz, 1β-H), 2.66 (dd, 1H, J = 16.5 Hz, J = 5.2 Hz,
4α-H), 3.64 (t, 1H, J = 8.5 Hz, 17α-H), 7.12 (t, 2H, J = 8.5 Hz, 3”-H and 5”-H), 7.39 (m, 2H, 2”-H and
6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.7 (5′-CH3), 11.0 (C-18), 11.8 (C-19), 20.8 (C-11), 23.4 (C-15),
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27.4 (C-4), 29.2 (C-6), 30.5 (C-16), 31.3 (C-7), 34.8 (C-1), 35.8 (C-8), 36.3 (C-10), 36.8 (C-12), 42.5 (C-5),
42.8 (C-13), 51.0 (C-14), 54.1 (C-9), 81.9 (C-17), 115.0 (C-2), 115.8 (2C, J = 23.0 Hz, C-3” and C-5”), 126.4
(2C, J = 8.5 Hz, C-2” and C-6”), 135.3 (C-5′), 136.1 (C-1”), 148.6 (C-3), 161.4 (J = 246.6 Hz, C-4”); ESI-MS
423 [M+H]+.
17β-Hydroxy-1′-(4”-chlorophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4g)
According to the general procedure, 4-chlorophenylhydrazine hydrochloride (2g, 215 mg) was
used. Yield: 219 mg (83%, white solid); Mp 260–262 ◦C; Anal. Calcd. for C27H35ClN2O (439.04): C,
73.87; H, 8.04. Found: C, 73.73; H, 8.09. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.79 (s,
3H, 19-H3), 0.83–1.01 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.8, J = 4.1 Hz,
12α-H), 1.27 (m, 1H, 15β-H), 1.33–1.50 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.53–1.65
(overlapping m, 3H, 5α-H, 15α-H and 6α-H), 1.66–1.75 (overlapping m, 2H, 11α-H and 7β-H), 1.86
(m, 1H, 12β-H), 2.05 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.20 (s, 3H, 5′-CH3), 2.33 (dd, 1H,
J = 16.8 Hz, J = 12.1 Hz, 4β-H), 2.51 (d, 1H, J = 15.0 Hz, 1β-H), 2.65 (dd, 1H, J = 16.5 Hz, J = 5.2 Hz,
4α-H), 3.64 (t, 1H, J = 8.6 Hz, 17α-H), 7.35–7.41 (overlapping m, 4H, 2”-H, 3”-H, 5”-H and 6”-H); 13C
NMR (CDCl3, 125 MHz): δ 10.9 (5′-CH3), 11.0 (C-18), 11.8 (C-19), 20.8 (C-11), 23.4 (C-15), 27.4 (C-4),
29.2 (C-6), 30.5 (C-16), 31.3 (C-7), 34.8 (C-1), 35.8 (C-8), 36.2 (C-10), 36.7 (C-12), 42.5 (C-5), 42.8 (C-13),
50.9 (C-14), 54.1 (C-9), 81.9 (C-17), 115.4 (C-2), 125.5 (2C, C-2” and C-6”), 129.1 (2C, C-3” and C-5”),
132.5 (C-4”), 135.2 (C-5′), 138.5 (C-1”), 149.0 (C-3); ESI-MS 440 [M+H]+.
17β-Hydroxy-1′-(4”-bromophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4h)
According to the general procedure, 4-bromophenylhydrazine hydrochloride (2h, 268 mg) was
used. Yield: 232 mg (80%, white solid); Mp 256–259 ◦C; Anal. Calcd. for C27H35BrN2O (483.49): C,
67.07; H, 7.30. Found: C, 67.16; H, 7.38. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.79 (s,
3H, 19-H3), 0.83–1.01 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.7, J = 3.5 Hz,
12α-H), 1.27 (m, 1H, 15β-H), 1.33–1.50 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.52–1.64
(overlapping m, 3H, 5α-H, 15α-H and 6α-H), 1.66–1.75 (overlapping m, 2H, 11α-H and 7β-H), 1.86
(m, 1H, 12β-H), 2.05 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.20 (s, 3H, 5′-CH3), 2.32 (dd, 1H,
J = 16.6 Hz, J = 12.4 Hz, 4β-H), 2.51 (d, 1H, J = 15.0 Hz, 1β-H), 2.66 (dd, 1H, J = 16.6 Hz, J = 4.9 Hz,
4α-H), 3.64 (t, 1H, J = 8.6 Hz, 17α-H), 7.32 (d, 2H, J = 8.5 Hz, 3”-H and 5”-H), 7.55 (d, 2H, J = 8.5 Hz,
2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 11.0 (5′-CH3), 11.0 (C-18), 11.8 (C-19), 20.8 (C-11), 23.4
(C-15), 27.4 (C-4), 29.2 (C-6), 30.6 (C-16), 31.3 (C-7), 34.8 (C-1), 35.8 (C-8), 36.2 (C-10), 36.8 (C-12), 42.4
(C-5), 42.8 (C-13), 50.9 (C-14), 54.1 (C-9), 81.9 (C-17), 115.5 (C-2), 120.4 (C-4”), 125.8 (2C, C-2” and C-6”),
132.0 (2C, C-3” and C-5”), 135.2 (C-5′), 138.9 (C-1”), 149.0 (C-3); ESI-MS 484 [M+H]+.
17β-Hydroxy-1′-(4”-cyanophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4i)
According to the general procedure, 4-cianophenylhydrazine hydrochloride (2i, 204 mg) was
used. Yield: 209 mg (81%, white solid); Mp 247–250 ◦C; Anal. Calcd. for C28H35N3O (429.61): C,
78.28; H, 8.21. Found: C, 78.12; H, 8.15. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.79 (s,
3H, 19-H3), 0.84–1.02 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.11 (td, 1H, J = 12.7, J = 3.6 Hz,
12α-H), 1.28 (m, 1H, 15β-H), 1.33–1.51 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.52–1.65
(overlapping m, 3H, 5α-H, 15α-H and 6α-H), 1.67–1.76 (overlapping m, 2H, 11α-H and 7β-H), 1.86
(m, 1H, 12β-H), 2.06 (d + m, 2H, J = 15.3 Hz, 1α-H and 16α-H), 2.29 (s, 3H, 5′-CH3), 2.34 (dd, 1H,
J = 16.9 Hz, J = 12.4 Hz, 4β-H), 2.53 (d, 1H, J = 15.3 Hz, 1β-H), 2.67 (dd, 1H, J = 16.9 Hz, J = 5.0 Hz,
4α-H), 3.64 (t, 1H, J = 8.5 Hz, 17α-H), 7.61 (d, 2H, J = 8.9 Hz, 2”-H and 6”-H), 7.72 (d, 2H, J = 8.9 Hz,
3”-H and 5”-H); 13C NMR (CDCl3, 125 MHz): δ 11.0 (C-18), 11.5 (5′-CH3), 11.8 (C-19), 20.8 (C-11), 23.4
(C-15), 27.4 (C-4), 29.2 (C-6), 30.6 (C-16), 31.3 (C-7), 34.7 (C-1), 35.8 (C-8), 36.2 (C-10), 36.7 (C-12), 42.3
(C-5), 42.8 (C-13), 50.9 (C-14), 54.0 (C-9), 81.9 (C-17), 109.8 (C-4”), 117.0 (C-2), 118.4 (CN), 123.7 (2C, C-2”
and C-6”), 133.1 (2C, C-3” and C-5”), 135.5 (C-5′), 143.4 (C-1”), 150.3 (C-3); ESI-MS 430 [M+H]+.
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17β-Hydroxy-1′-(4”-nitrophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androstane (4j)
According to the general procedure, 4-nitrophenylhydrazine hydrochloride (2j, 228 mg) was used.
Yield: 229 mg (85%, yellow solid); Mp 238–240 ◦C; Anal. Calcd. for C27H35N3O3 (449.60): C, 72.13; H,
7.85. Found: C, 72.04; H, 7.76. 1H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H, 18-H3), 0.80 (s, 3H, 19-H3),
0.84–1.02 (overlapping m, 3H, 9α-H, 7α-H and 14α-H), 1.12 (td, 1H, J = 12.7, J = 3.6 Hz, 12α-H), 1.28
(m, 1H, 15β-H), 1.33–1.51 (overlapping m, 4H, 6β-H, 8β-H, 16β-H and 11β-H), 1.53–1.66 (overlapping
m, 3H, 5α-H, 15α-H and 6α-H), 1.67–1.76 (overlapping m, 2H, 11α-H and 7β-H), 1.87 (m, 1H, 12β-H),
2.06 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.32 (s, 3H, 5′-CH3), 2.34 (m, 1H, 4β-H), 2.54 (d, 1H,
J = 15.0 Hz, 1β-H), 2.67 (dd, 1H, J = 17.0 Hz, J = 5.1 Hz, 4α-H), 3.64 (t, 1H, J = 8.5 Hz, 17α-H), 7.67 (d,
2H, J = 9.0 Hz, 2”-H and 6”-H), 8.30 (d, 2H, J = 9.0 Hz, 3”-H and 5”-H); 13C NMR (CDCl3, 125 MHz): δ
11.0 (C-18), 11.6 (5′-CH3), 11.8 (C-19), 20.8 (C-11), 23.4 (C-15), 27.4 (C-4), 29.2 (C-6), 30.5 (C-16), 31.3
(C-7), 34.7 (C-1), 35.8 (C-8), 36.2 (C-10), 36.7 (C-12), 42.3 (C-5), 42.8 (C-13), 50.9 (C-14), 54.0 (C-9), 81.9
(C-17), 117.0 (C-2), 123.2 (2C, C-2” and C-6”), 124.7 (2C, C-3” and C-5”), 135.7 (C-5′), 145.0 and 145.4
(C-1” and C-4”), 150.7 (C-3); ESI-MS 450 [M+H]+.
3.1.4. General Procedure for the Synthesis of Compounds 5a–j by Jones Oxidation
Compound 4a–j (0.25 mmol) was dissolved in acetone (10 mLl) and Jones reagent (0.2 mLl) was
added dropwise into the solution, which was then stirred at room temperature for 20 min, and after
the given reaction time diluted with water (15 mLl). The precipitate that formed was extracted with
CH2Cl2 (3× 10 mLl), and the combined organic phases were washed with water (10 mLl), then dried
over anhydrous Na2SO4 and concentrated in vacuo. The crude product was purified by column
chromatography with EtOAc/CH2Cl2 = 2:98.
1′-Phenyl-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5a)
According to the general procedure, 4a (101 mg) was used. Yield: 96 mg (96%, white solid); Mp
247–250 ◦C; Anal. Calcd. for C27H34N2O (402.58): C, 80.55; H, 8.51. Found: C, 80.60; H, 8.59. 1H NMR
(CDCl3, 500 MHz): δ 0.83 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.94 (m, 1H), 1.04 (m, 1H), 1.27–1.35
(overlapping m, 2H), 1.37–1.63 (overlapping m, 5H), 1.69 (m, 1H), 1.79 (m, 1H), 1.83–1.89 (overlapping
m, 2H), 1.98 (m, 1H), 2.08 (d + m, 2H, J = 15.2 Hz, 1α-H and 16α-H), 2.21 (s, 3H, 5′-CH3), 2.36 (dd, 1H,
J = 16.7 Hz, J = 12.1 Hz, 4β-H), 2.46 (dd, 1H, J = 19.2 Hz, J = 8.8 Hz, 16β-H), 2.52 (d, 1H, J = 15.2 Hz,
1β-H2), 2.69 (dd, 1H, J = 16.7 Hz, J = 5.1 Hz, 4α-H), 7.31 (m, 1H, 4”-H), 7.43 (d, 4H, J = 4.4 Hz, 2”-H,
3”-H, 5”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.9 (5′-CH3), 11.7 (C-19), 13.7 (C-18), 20.5 (C-11),
21.8 (C-15), 27.5 (C-4), 29.1 (C-6), 30.6 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8), 35.8 (C-16), 36.4 (C-10),
42.5 (C-5), 47.6 (C-13), 51.4 (C-14), 54.1 (C-9), 114.8 (C-2), 124.5 (2C, C-2” and C-6”), 127.0 (C-4”), 128.9
(2C, C-3” and C-5”), 135.2 (C-5′), 139.9 (C-1”), 148.4 (C-3), 221.2 (C-17); ESI-MS 403 [M+H]+.
1′-(2”-Tolyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5b)
According to the general procedure, 4b (105 mg) was used. Yield: 97 mg (93%, white solid); Mp
245–250 ◦C; Anal. Calcd. for C28H36N2O (416.61): C, 80.73; H, 8.71. Found: C, 80.61; H, 8.77. 1H NMR
(CDCl3, 500 MHz): δ 0.83 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.94 (m, 1H), 1.04 (m, 1H), 1.27–1.35
(overlapping m, 2H), 1.37–1.64 (overlapping m, 5H), 1.68 (m, 1H), 1.79 (m, 1H), 1.83–1.89 (overlapping
m, 2H), 1.95 (s, 3H), 1.98 (m, 1H), 2.03 (s, 3H), 2.09 (d + m, 2H, J = 15.1 Hz, 1α-H and 16α-H), 2.36 (dd,
1H, J = 16.5 Hz, J = 12.2 Hz, 4β-H), 2.46 (dd, 1H, J = 19.2 Hz, J = 8.8 Hz, 16β-H), 2.52 (d, 1H, J = 15.1 Hz,
1β-H2), 2.68 (dd, 1H, J = 16.5 Hz, J = 4.9 Hz, 4α-H), 7.19–7.32 (overlapping m, 4H, 3”-H, 4”-H, 5”-H
and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 9.7 (5′-CH3), 11.7 (C-19), 13.7 (C-18), 17.3 (2”-CH3), 20.5
(C-11), 21.8 (C-15), 27.5 (C-4), 29.1 (C-6), 30.7 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8), 35.8 (C-16), 36.4
(C-10), 42.5 (C-5), 47.6 (C-13), 51.4 (C-14), 54.1 (C-9), 112.9 (C-2), 126.3 (CH), 127.9 (CH), 128.7 (CH),
130.7 (CH), 136.1, 136.2 and 138.8 (C-5′, C-1” and C-2”), 147.7 (C-3), 221.2 (C-17); ESI-MS 417 [M+H]+.
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1′-(4”-Tolyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5c)
According to the general procedure, 4c (105 mg) was used. Yield: 96 mg (92%, white solid); Mp
241–243 ◦C; Anal. Calcd. for C28H36N2O (416.61): C, 80.73; H, 8.71. Found: C, 80.79; H, 8.78. 1H NMR
(CDCl3, 500 MHz): δ 0.83 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.93 (m, 1H), 1.04 (m, 1H), 1.28–1.35
(overlapping m, 2H), 1.38–1.63 (overlapping m, 5H), 1.69 (m, 1H), 1.79 (m, 1H), 1.84–1.90 (overlapping
m, 2H), 1.98 (m, 1H), 2.09 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.18 (s, 3H, 5′-CH3), 2.36 (m, 1H,
4β-H), 2.38 (4”-CH3), 2.46 (dd, 1H, J = 19.3 Hz, J = 9.0 Hz, 16β-H), 2.52 (d, 1H, J = 15.0 Hz, 1β-H2), 2.70
(dd, 1H, J = 16.7 Hz, J = 4.6 Hz, 4α-H), 7.23 (d, 2H, J = 8.0 Hz, 3”-H and 5”-H), 7.30 (d, 2H, J = 8.0 Hz,
2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.8 (5′-CH3), 11.8 (C-19), 13.7 (C-18), 20.5 (C-11), 21.0
(4”-CH3), 21.8 (C-15), 27.4 (C-4), 29.0 (C-6), 30.6 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8), 35.8 (C-16),
36.4 (C-10), 42.5 (C-5), 47.6 (C-13), 51.4 (C-14), 54.1 (C-9), 114.5 (C-2), 124.5 (2C, C-2” and C-6”), 129.5
(2C, C-3” and C-5”), 136.9, 137.0 and 137.3 (C-5′, C-1” and C-4”), 148.0 (C-3), 221.2 (C-17); ESI-MS 417
[M+H]+.
1′-(2”,4”-Dimethylphenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5d)
According to the general procedure, 4d (108 mg) was used. Yield: 101 mg (94%, white solid); Mp
173–176 ◦C; Anal. Calcd. for C29H38N2O (430.64): C, 80.88; H, 8.89. Found: C, 80.98; H, 8.93. 1H NMR
(CDCl3, 500 MHz): δ 0.82 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.94 (m, 1H), 1.04 (m, 1H), 1.28–1.35
(overlapping m, 2H), 1.37–1.63 (overlapping m, 5H), 1.68 (m, 1H), 1.79 (m, 1H), 1.84–1.90 (overlapping
m, 2H), 1.94 (s, 3H), 1.99 (s + m, 4H), 2.09 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.35 (s + m, 4H,
4”-CH3 and 4β-H), 2.46 (dd, 1H, J = 19.5 Hz, J = 9.0 Hz, 16β-H), 2.51 (d, 1H, J = 15.0 Hz, 1β-H2), 2.68
(dd, 1H, J = 16.7 Hz, J = 4.5 Hz, 4α-H), 7.01–7.10 (overlapping m, 3H, 3”-H, 5”-H and 6”-H); 13C NMR
(CDCl3, 125 MHz): δ 9.7 (5′-CH3), 11.7 (C-19), 13.7 (C-18), 17.2 (2”-CH3), 20.5 (C-11), 21.1 (4”-CH3),
21.8 (C-15), 27.5 (C-4), 29.1 (C-6), 30.7 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8), 35.8 (C-16), 36.4 (C-10),
42.4 (C-5), 47.6 (C-13), 51.4 (C-14), 54.1 (C-9), 112.8 (C-2), 127.0, 127.6 and 131.4 (C-3”, C-5” and C-6”),
135.8, 135.9, 136.3 and 138.7 (C-5′, C-1”, C-2” and C-4”), 147.4 (C-3), 221.2 (C-17); ESI-MS 431 [M+H]+.
1′-(4”-Methoxyphenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5e)
According to the general procedure, 4e (109 mg) was used. Yield: 99 mg (92%, white solid); Mp
225–226 ◦C; Anal. Calcd. for C28H36N2O2 (432.61): C, 77.74; H, 8.39. Found: C, 77.68; H, 8.48. 1H NMR
(CDCl3, 500 MHz): δ 0.82 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.93 (m, 1H), 1.04 (m, 1H), 1.27–1.34
(overlapping m, 2H), 1.37–1.63 (overlapping m, 5H), 1.68 (m, 1H), 1.78 (m, 1H), 1.83–1.89 (overlapping
m, 2H), 1.98 (m, 1H), 2.08 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.15 (s, 3H, 5′-CH3), 2.36 (dd, 1H,
J = 16.6 Hz, J = 12.3 Hz, 4β-H), 2.46 (dd, 1H, J = 19.4 Hz, J = 9.0 Hz, 16β-H), 2.51 (d, 1H, J = 15.2 Hz,
1β-H2), 2.70 (dd, 1H, J = 16.6 Hz, J = 4.8 Hz, 4α-H), 3.83 (4”-OMe), 6.94 (d, 2H, J = 8.8 Hz, 3”-H and
5”-H), 7.32 (d, 2H, J = 8.8 Hz, 2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.6 (5′-CH3), 11.8 (C-19),
13.7 (C-18), 20.5 (C-11), 21.8 (C-15), 27.4 (C-4), 29.0 (C-6), 30.6 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8),
35.8 (C-16), 36.4 (C-10), 42.4 (C-5), 47.6 (C-13), 51.4 (C-14), 54.1 (C-9), 55.5 (4”-OMe), 114.1 (2C, C-2”
and C-6”), 114.2 (C-2), 126.2 (2C, C-3” and C-5”), 132.3 (C-1”), 135.5 (C-5′), 147.7 (C-3), 158.7 (C-4”),
221.2 (C-17); ESI-MS 433 [M+H]+.
1′-(4”-Fluorophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5f)
According to the general procedure, 4f (106 mg) was used. Yield: 100 mg (95%, white solid);
Mp 208–210 ◦C; Anal. Calcd. for C27H33FN2O (420.57): C, 77.11; H, 7.91. Found: C, 77.23; H, 7.99.
1H NMR (CDCl3, 500 MHz): δ 0.81 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.93 (m, 1H), 1.03 (m, 1H),
1.27–1.34 (overlapping m, 2H), 1.37–1.61 (overlapping m, 5H), 1.68 (m, 1H), 1.78 (m, 1H), 1.83–1.89
(overlapping m, 2H), 1.97 (m, 1H), 2.08 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.17 (s, 3H, 5′-CH3),
2.36 (dd, 1H, J = 16.6 Hz, J = 12.3 Hz, 4β-H), 2.45 (dd, 1H, J = 19.2 Hz, J = 8.9 Hz, 16β-H), 2.51 (d, 1H,
J = 15.2 Hz, 1β-H2), 2.67 (dd, 1H, J = 16.6 Hz, J = 4.9 Hz, 4α-H), 7.11 (t, 2H, J = 8.4 Hz, 3”-H and 5”-H),
7.38 (m, 2H, 2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.6 (5′-CH3), 11.7 (C-19), 13.7 (C-18), 20.5
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(C-11), 21.8 (C-15), 27.4 (C-4), 29.0 (C-6), 30.6 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8), 35.8 (C-16), 36.3
(C-10), 42.4 (C-5), 47.6 (C-13), 51.4 (C-14), 54.0 (C-9), 114.8 (C-2), 115.5 (2C, J = 22.8 Hz, C-3” and C-5”),
126.3 (2C, J = 8.5 Hz, C-2” and C-6”), 135.4 (C-5′), 136.1 (C-1”), 148.4 (C-3), 161.5 (J = 247.1 Hz, C-4”),
221.2 (C-17); ESI-MS 421 [M+H]+.
1′-(4”-Chlorophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5g)
According to the general procedure, 4g (110 mg) was used. Yield: 102 mg (93%, white solid);
Mp 200–203 ◦C; Anal. Calcd. for C27H33ClN2O (437.02): C, 74.21; H, 7.61. Found: C, 74.09; H, 7.67.
1H NMR (CDCl3, 500 MHz): δ 0.81 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.93 (m, 1H), 1.04 (m, 1H),
1.27–1.35 (overlapping m, 2H), 1.37–1.62 (overlapping m, 5H), 1.69 (m, 1H), 1.78 (m, 1H), 1.83–1.89
(overlapping m, 2H), 1.98 (m, 1H), 2.08 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.20 (s, 3H, 5′-CH3),
2.35 (dd, 1H, J = 16.8 Hz, J = 12.1 Hz, 4β-H), 2.46 (dd, 1H, J = 19.2 Hz, J = 8.9 Hz, 16β-H), 2.52 (d, 1H,
J = 15.0 Hz, 1β-H2), 2.69 (dd, 1H, J = 16.8 Hz, J = 5.1 Hz, 4α-H), 7.35–7.42 (overlapping m, 4H, 2”-H,
3”-H, 5”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 10.9 (5′-CH3), 11.7 (C-19), 13.7 (C-18), 20.5 (C-11),
21.8 (C-15), 27.4 (C-4), 29.0 (C-6), 30.6 (C-12), 31.6 (C-7), 34.7 (C-1), 35.3 (C-8), 35.8 (C-16), 36.3 (C-10),
42.4 (C-5), 47.6 (C-13), 51.4 (C-14), 54.0 (C-9), 115.2 (C-2), 125.5 (2C, C-2” and C-6”), 129.1 (2C, C-3” and
C-5”), 132.7 (C-4”), 135.4 (C-5′), 138.4 (C-1”), 148.7 (C-3), 221.2 (C-17); ESI-MS 438 [M+H]+.
1′-(4”-Bromophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5h)
According to the general procedure, 4h (121 mg) was used. Yield: 110 mg (92%, white solid);
Mp 239–242 ◦C; Anal. Calcd. for C27H33BrN2O (481.48): C, 67.35; H, 6.91. Found: C, 67.50; H, 6.99.
1H NMR (CDCl3, 500 MHz): δ 0.81 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.93 (m, 1H), 1.04 (m, 1H),
1.27–1.34 (overlapping m, 2H), 1.37–1.62 (overlapping m, 5H), 1.69 (m, 1H), 1.78 (m, 1H), 1.84–1.89
(overlapping m, 2H), 1.98 (m, 1H), 2.07 (d + m, 2H, J = 15.0 Hz, 1α-H and 16α-H), 2.20 (s, 3H, 5′-CH3),
2.34 (dd, 1H, J = 16.7 Hz, J = 12.4 Hz, 4β-H), 2.46 (dd, 1H, J = 19.3 Hz, J = 8.9 Hz, 16β-H), 2.52 (d, 1H,
J = 15.0 Hz, 1β-H2), 2.68 (dd, 1H, J = 16.7 Hz, J = 5.1 Hz, 4α-H), 7.32 (d, 2H, J = 8.6 Hz, 3”-H and 5”-H),
7.55 (d, 2H, J = 8.6 Hz, 2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 11.0 (5′-CH3), 11.7 (C-19), 13.7
(C-18), 20.5 (C-11), 21.8 (C-15), 27.4 (C-4), 29.0 (C-6), 30.6 (C-12), 31.6 (C-7), 34.8 (C-1), 35.3 (C-8), 35.8
(C-16), 36.3 (C-10), 42.4 (C-5), 47.6 (C-13), 51.4 (C-14), 54.0 (C-9), 115.3 (C-2), 120.4 (C-4”), 125.8 (2C, C-2”
and C-6”), 132.0 (2C, C-3” and C-5”), 135.2 (C-5′), 139.0 (C-1”), 148.9 (C-3), 221.2 (C-17); ESI-MS 482
[M+H]+.
1′-(4”-Cyanophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5i)
According to the general procedure, 4i (107 mg) was used. Yield: 98 mg (92%, white solid); Mp
234–237 ◦C; Anal. Calcd. for C28H33N3O (427.59): C, 78.65; H, 7.78. Found: C, 78.76; H, 7.87. 1H NMR
(CDCl3, 500 MHz): δ 0.81 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.94 (m, 1H), 1.05 (m, 1H), 1.27–1.35
(overlapping m, 2H), 1.37–1.62 (overlapping m, 5H), 1.70 (m, 1H), 1.79 (m, 1H), 1.84–1.90 (overlapping
m, 2H), 1.98 (m, 1H), 2.08 (d + m, 2H, J = 15.1 Hz, 1α-H and 16α-H), 2.29 (s, 3H, 5′-CH3), 2.35 (dd, 1H,
J = 16.8 Hz, J = 12.4 Hz, 4β-H), 2.47 (dd, 1H, J = 19.2 Hz, J = 8.7 Hz, 16β-H), 2.54 (d, 1H, J = 15.1 Hz,
1β-H2), 2.69 (dd, 1H, J = 16.8 Hz, J = 5.1 Hz, 4α-H), 7.61 (d, 2H, J = 8.6 Hz, 3”-H and 5”-H), 7.72 (d, 2H,
J = 8.6 Hz, 2”-H and 6”-H); 13C NMR (CDCl3, 125 MHz): δ 11.5 (5′-CH3), 11.8 (C-19), 13.7 (C-18), 20.5
(C-11), 21.8 (C-15), 27.4 (C-4), 29.0 (C-6), 30.6 (C-12), 31.6 (C-7), 34.7 (C-1), 35.3 (C-8), 35.8 (C-16), 36.3
(C-10), 42.3 (C-5), 47.6 (C-13), 51.4 (C-14), 54.0 (C-9), 109.8 (C-4”), 116.7 (C-2), 118.4 (CN), 123.7 (2C, C-2”
and C-6”), 133.1 (2C, C-3” and C-5”), 135.4 (C-5′), 143.5 (C-1”), 150.3 (C-3); 221.1 (C-17); ESI-MS 428
[M+H]+.
1′-(4”-Nitrophenyl)-5′-methylpyrazolo[3′,4′:3,2]-5α-androst-17-one (5j)
According to the general procedure, 4j (112 mg) was used. Yield: 107 mg (96%, yellow solid); Mp
140–143 ◦C; Anal. Calcd. for C27H33N3O3 (447.58): C, 72.46; H, 7.43. Found: C, 72.55; H, 7.34. 1H NMR
(CDCl3, 500 MHz): δ 0.81 (s, 3H, 19-H3), 0.90 (s, 3H, 18-H3), 0.94 (m, 1H), 1.05 (m, 1H), 1.27–1.35
(overlapping m, 2H), 1.37–1.62 (overlapping m, 5H), 1.70 (m, 1H), 1.79 (m, 1H), 1.84–1.90 (overlapping
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m, 2H), 1.98 (m, 1H), 2.08 (d + m, 2H, J = 15.1 Hz, 1α-H and 16α-H), 2.33 (s, 3H, 5′-CH3), 2.35 (m, 1H,
4β-H), 2.46 (dd, 1H, J = 19.1 Hz, J = 8.7 Hz, 16β-H), 2.54 (d, 1H, J = 15.1 Hz, 1β-H2), 2.69 (dd, 1H,
J = 16.8 Hz, J = 4.7 Hz, 4α-H), 7.66 (d, 2H, J = 8.9 Hz, 2”-H and 6”-H), 8.30 (d, 2H, J = 8.9 Hz, 3”-H and
5”-H); 13C NMR (CDCl3, 125 MHz): δ 11.7 (5′-CH3), 11.8 (C-19), 13.7 (C-18), 20.5 (C-11), 21.8 (C-15),
27.4 (C-4), 29.0 (C-6), 30.5 (C-12), 31.6 (C-7), 34.7 (C-1), 35.3 (C-8), 35.8 (C-16), 36.3 (C-10), 42.3 (C-5),
47.6 (C-13), 51.3 (C-14), 54.0 (C-9), 117.1 (C-2), 123.1 (2C, C-2” and C-6”), 124.7 (2C, C-3” and C-5”),
135.5 (C-5′), 145.2 and 145.3 (C-1” and C-4”), 150.6 (C-3); 221.1 (C-17); ESI-MS 448 [M+H]+.
3.2. Pharmacology
3.2.1. Cell Culture
HeLa, MCF-7 and MDA-MB-231 cells were obtained from Sigma-Aldrich and maintained as
reported previously [22]. MRC-5, PC-3, DU 145 cells were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). PC-3 and DU 145 were maintained in RPMI medium
(Sigma-Aldrich) whereas MRC-5 cells were maintained in DMEM medium (Sigma-Aldrich). All media
were complemented with 10% Fetal bovine serum (FBS, Sigma-Aldrich) 2 mM L-glutamine, 0.01%
streptomycin and 0.005% ampicillin (Sigma-Aldrich). Cells were cultured under standard conditions
in a 37 ◦C incubator containing 5% CO2 in 95% humidity.
3.2.2. Cell Viability Assay
Each test compound was dissolved in cell culture grade DMSO (Molar Chemicals, Halásztelek,
Hungary) in a final concentration of 10 mM. Antiproliferative action of the synthesized steroids was
investigated by MTT assay. An amount of 5000 cells/well were seeded into 96 well plates. Twenty-four
hours post seeding, all cell lines were treated with each compound in 10 and 30 µM concentrations
for 72 hours. To identify the IC50 values, seeded cells were exposed to selected compounds in 0, 0.5,
1, 2, 3, 5, 10 and 15 µM concentrations. After 72 hours, cells were washed with PBS and incubated
with culture medium containing 0.5 mg/mL MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium
bromide) reagent (SERVA, GmbH, Heidelberg, Germany) for an hour at 37 ◦C. Formazan crystals
were solubilized in DMSO and extinction was measured at 570 nm using a Synergy HTX plate reader
(BioTech-Hungary, Budapest, Hungary). MTT assays were performed at least three times using
four independent biological replicates. Data were normalized to solvent controls and the graphical
representation of the obtained data as well as the calculation of IC50 values were carried out by
GraphPad Prism 7 software (GraphPad Software; San Diego, CA, USA).
3.2.3. Apoptosis Detection
PC-3 cells were seeded at 2 × 106 cells/well density in 6-well plates. On the following day cells
were treated with 5 µM of either compound 4e or 4j or with 200 µM of cisplatin (Accord Healthcare
Ltd., Middlesex, UK). After 48-hour treatment, cells were collected and a Dead Cell Apoptosis Kit
containing AnnexinV-FITC and propidium iodide (Life Technologies-Hungary, Budapest, Hungary)
was used according to the manufacturer’s recommendation. Fluorescence intensities of at least 10,000
cells/sample were measured by FACSCalibur™ (BD Biosciences, Franklin Lakes, CA, USA) and data
were analyzed by FlowJo V10 software (BD Biosciences, Franklin Lakes, NJ, USA). Experiments were
repeated three times using triplicates.
3.2.4. Reverse Transcription and Real-Time qPCR
PC-3 cells were seeded at 2 × 106 cells/well density in 6 well plates. On the following day
cells were treated with 5 µM of either compound 4e or 4j or with 200 µM of cisplatin. Cells were
collected 48-hours post-treatment and total cellular RNA was isolated using RNeasy® Mini Kit
(QIAGEN, Hilden, Germany) according to the manufacturer’s recommendation. RNA (2 µg) was
reverse transcribed (TaqMan® Reverse Transcription kit, Applied Biosystems, Foster City, CA, USA) in
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50 µL total volume. PCR reactions were performed on PicoReal™ Real-time PCR (Thermo Scientific,
Walthan, MA, USA) using SYBRGreen qPCR Master Mix (Thermo Scientific) with an input of 1 µL
cDNA. Each primer (Table 3) was used at 200 nM concentration. Relative transcript levels were
determined by the ∆∆Ct analysis using GAPDH as reference gene. Experiments were repeated three
times with three biological replicates.
Table 3. Primers and their sequences used for RT-qPCR analysis.
Target FWD primer REV primer
Caspase-3 5′-ACATGGCGTGTCATAAAATACC-3′ 5′-CACAAAGCGACTGGATGAAC-3′
Bax 5′-TGCTTCAGGGTTTCATCCAG-3′ 5′-GGCGGCAATCATCCTCTG-3′
Gapdh 5′-GCACCACCAACTGCTTAGC-3′ 5′-GGCATGGACTGTGGTCATGAG-3′
3.2.5. Statistical Analysis
Data are presented as the mean ± standard deviation (SD). GraphPad prism software was used to
evaluate statistical differences by one-way analysis of variance (ANOVA) followed by Fisher’s LSD
tests. Criterion for statistical significance was set at p < 0.05. The representative significance values as
per Fisher’s LSD test are * p < 0.03, ** p < 0.002, *** p < 0.0002, **** p < 0.0001.
4. Conclusions
Despite numerous promising treatment modalities such as radiation therapy, surgical resection
and hormone therapy, prostate cancer remains one of the top most common causes of cancer-related
deaths among men worldwide. Prostate cancers that are insensitive to androgen blockade or those
which are hormone-refractory after hormone and radiotherapy are the most challenging. In addition,
the frequently observed loss of p53 function significantly affects the drug-induced apoptotic elimination
of cancer cells. Current attempts focus on developing drugs capable of stimulating apoptosis in a
p53-independent manner. For this purpose, a number of novel ring A-fused arylpyrazoles in the
androstane series were synthesized and structurally characterized by 1D and 2D NMR methods.
Heterocyclization reactions of a DHT-derived α,β-enone with arylhydrazines occurred regio-selectively
both under conventional and MW heating conditions, but the resulting pyrazolines were obtained
as mixtures of diastereomers due to the newly-formed chiral centers and were found to undergo at
least partial autoxidation to pyrazoles. Therefore, the cyclizations were repeated under MW-assisted
oxidative conditions in the presence of I2, which afforded the desired pyrazoles in good yields
independently of the substituents of the reagents applied. The 17-oxo analogs of the heteroaromatic
steroids were also prepared by Jones oxidation. According to the pharmacological studies, the novel
ring A-fused arylpyrazole derivatives of DHT developed by our laboratory manifested a prominent
structure-function relationship, where derivatives carrying a hydroxyl group on C-17 exhibited stronger
anti-cancer activity compared to the 17-one counterparts. Moreover, some of the prepared analogs
exhibited substantial cancer cell specific antiproliferative action and proapoptotic features on androgen
therapy refractive p53-deficient PC-3 cells initiated by intrinsic pathways of apoptosis. Based on these
conclusions further targeted design, synthesis and investigations of DHT analogs can be achieved.
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